Critical Analysis: Sigyn Therapeutics (OTCMKTS:SIGY) and Shuttle Pharmaceuticals (NASDAQ:SHPH)

Sigyn Therapeutics (OTCMKTS:SIGY) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Sigyn Therapeutics and Shuttle Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sigyn Therapeutics	0	0	0	0	0.00
Shuttle Pharmaceuticals	1	0	0	0	1.00

Profitability

This table compares Sigyn Therapeutics and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	-3,743.20%
Shuttle Pharmaceuticals	N/A	-444.90%	-188.81%

Valuation and Earnings

This table compares Sigyn Therapeutics and Shuttle Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$3.34 million	($4.19)	-0.01
Shuttle Pharmaceuticals	N/A	N/A	-$11.72 million	($11.84)	-0.07

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Sigyn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.0% of Sigyn Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 78.5% of Sigyn Therapeutics shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Sigyn Therapeutics has a beta of -0.47, suggesting that its stock price is 147% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500.

Summary

Sigyn Therapeutics beats Shuttle Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.